Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

  • The following term was not found in PubMed: Lars-Henrik.
1.

In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery.

Waters S, Svensson P, Kullingsjö J, Pontén H, Andreasson T, Sunesson Y, Ljung E, Sonesson C, Waters N.

ACS Chem Neurosci. 2017 Apr 19;8(4):785-797. doi: 10.1021/acschemneuro.6b00371. Epub 2017 Jan 9.

2.

Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington's disease.

Urbach YK, Raber KA, Canneva F, Plank AC, Andreasson T, Ponten H, Kullingsjö J, Nguyen HP, Riess O, von Hörsten S.

J Neurosci Methods. 2014 Aug 30;234:38-53. doi: 10.1016/j.jneumeth.2014.06.017. Epub 2014 Jul 11.

PMID:
25020253
3.

The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model.

Ponten H, Kullingsjö J, Sonesson C, Waters S, Waters N, Tedroff J.

Eur J Pharmacol. 2013 Jan 5;698(1-3):278-85. doi: 10.1016/j.ejphar.2012.10.039. Epub 2012 Nov 2.

PMID:
23127496
4.

Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.

Esmaeilzadeh M, Kullingsjö J, Ullman H, Varrone A, Tedroff J.

Clin Neuropharmacol. 2011 May-Jun;34(3):95-100. doi: 10.1097/WNF.0b013e31821c31d8.

PMID:
21586914
5.

In vivo pharmacology of the dopaminergic stabilizer pridopidine.

Ponten H, Kullingsjö J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, Waters S, Waters N.

Eur J Pharmacol. 2010 Oct 10;644(1-3):88-95. doi: 10.1016/j.ejphar.2010.07.023. Epub 2010 Jul 24.

6.

Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy.

Wikell C, Apelqvist G, Hjorth S, Kullingsjö J, Bergqvist PB, Bengtsson F.

Eur Neuropsychopharmacol. 2002 Aug;12(4):327-36.

PMID:
12126872
7.

Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings.

Wikell C, Hjorth S, Apelqvist G, Kullingsjö J, Lundmark J, Bergqvist PB, Bengtsson F.

Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):448-55.

PMID:
11330339
8.
9.

Pharmacokinetics of alprazolam in geriatric patients with neurotic depression.

Dehlin O, Kullingsjö H, Lidén A, Agrell B, Moser G, Olsen I.

Pharmacol Toxicol. 1991 Feb;68(2):121-4.

PMID:
1852717
10.

Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study.

Andersch S, Rosenberg NK, Kullingsjö H, Ottosson JO, Bech P, Bruun-Hansen J, Hanson L, Lorentzen K, Mellergård M, Rasmussen S, et al.

Acta Psychiatr Scand Suppl. 1991;365:18-27.

PMID:
1862730
11.

[Semi-annual report from Fall 88 to Spring 89].

Kullingsjö U.

Jordemodern. 1990 Apr;103(4):139-42. Swedish. No abstract available.

PMID:
2347745
12.

Comparison of nitrazepam with triazolam in insomniac outpatients.

Dahl LE, Dencker SJ, Lundin L, Kullingsjö H.

Acta Psychiatr Scand. 1982 Feb;65(2):86-92.

PMID:
6138924

Supplemental Content

Loading ...
Support Center